Nomacopan is currently being clinically evaluated in four indications: bullous pemphigoid (BP),
atopic keratoconjunctivitis (AKC), thrombotic microangiopathy (TMA), and paroxysmal nocturnal hemoglobinuria (PNH).
Based on type, the market has been classified into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis,
atopic keratoconjunctivitis, giant papillary conjunctivitis, and others.
Akari Therapeutics announced positive results for Part A of TRACKER, a Phase I/II clinical trial evaluating the safety and efficacy of topical nomacopan in moderate to severe
atopic keratoconjunctivitis. AKC is a serious corneal and eye surface disease which frequently progresses to visual impairment.
Systemic cyclosporine A in severe
atopic keratoconjunctivitis. Eur J Ophthalmol 2010; 20:844-51.
Coversin is being clinically evaluated in four indications: bullous pemphigoid (BP),
atopic keratoconjunctivitis (AKC), atypical hemolytic uremic syndrome (aHUS), and paroxysmal nocturnal hemoglobinuria (PNH).
[1] Allergic conjunctivitis is broadly divided into five subtypes: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC),
atopic keratoconjunctivitis (AKC) and giant papillary conjunctivitis (GPC).
Asano-Kato et al., "Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with
atopic keratoconjunctivitis," Clinical and Experimental Allergy, vol.
There are several more severe, although rare, forms of allergy, such as
atopic keratoconjunctivitis (AK) and vernal keratoconjunctivitis (VK).
Clinical features of
atopic keratoconjunctivitis. Ophthalmology.
This disorder can be divided into several categories: seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis and
atopic keratoconjunctivitis.
Atopic keratoconjunctivitis is a sight-threatening surface of the eye condition, and is currently in Phase I/II, with initial data anticipated in the first quarter of 2019.
To that end, two Phase II clinical trials, in the inflammatory-mediated eye disorder
Atopic Keratoconjunctivitis, or AKC, and in the skin inflammatory disease Bullous Pemphigoid, are anticipated to begin in the first half of 2018.
